Drugs / PRX-115
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05745727 | Mar 2023 → Aug 2024 | gout | Protalix | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07280156 | Dec 2025 → Dec 2027 expected | gout | Protalix | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRX-115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07280156 ↗ |
| Modality | Protein / enzyme biologic | “PRX-115 (a recombinant pegylated Uricase)” NCT07280156 ↗ |
| Route | Intravenous | “Participants will receive a single dose of PRX-115 by IV infusion” NCT05745727 ↗ |